arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

ADC Therapeutics SA

ADCT

$1.13 ▲ +0.01 (+0.89%) at close

8 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

ADC Therapeutics SA shows mixed fundamentals. On the positive side, Return on Common Equity (%) remains strong. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $143.6M

Dividend Yield —

Revenue Growth 14.9% ↗

Op. Margin -149.3% ↗

ROIC 51.7% →

FCF / Share $-1.11 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$81.36M

↑ +14.9% —

Net Income Profit after all expenses

$-142.62M

↑ +9.6% —

Operating Margin Operating profit as % of sales

-149.3%

↑ +19.0% 1th

FCF / Share Free cash flow per share

$-1.11

↑ +13.3% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓

Returns

Financial Health ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Revenue Growth YoY (%)	14.9% Good ↑ Good Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+86%)	1.8% Caution Caution Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-77%)	-66.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-936%)	—	—	—	—	—
EPS Growth YoY (%)	30.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	44.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-46.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	9.6% Fair ↑ Fair Improving Year-over-year change in net income	34.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-52.8% Weak ↓ Weak Declining Year-over-year change in net income	31.7% Excellent ↑ Excellent Improving Year-over-year change in net income	6.6% Fair ↑ Fair Improving Year-over-year change in net income	-111.4% Weak Weak Year-over-year change in net income	5.4% Fair Fair Year-over-year change in net income	—
FCF Growth YoY (%)	13.3% Fair ↓ Fair Declining Year-over-year change in free cash flow	14.0% Fair Fair Year-over-year change in free cash flow	16.1% Good Good Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	-27.1% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Operating Margin (%) (%)	-149.3% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1096%)	-184.4% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1330%)	-238.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1691%)	-58.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-492%)	—	—	—	—
Profit Margin (%) (%)	-175.3% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1561%)	-222.8% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1957%)	-345.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2976%)	-74.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-724%)	—	—	—	—
FCF Margin (%) (%)	-173.8% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-176.0% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-175.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-66.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.51x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Return on Invested Capital (%)	51.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	50.9% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	88.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	-122.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—
Return on Capital (%) (%)	-37.6% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-40.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-46.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-25.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	76.7% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+412%)	77.9% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+419%)	161.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+980%)	-197.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1418%)	—	—	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Interest Coverage (x)	-7.47x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-2.60x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-3.58x Weak Weak Operating income divided by interest expense Optimal: > 5x	-3.36x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-261.34M	$-250.87M	$-278.60M	$-326.44M	—	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Revenue per Share (USD)	$0.64	$0.73	$0.85	$2.69	—	—	—	—
Basic EPS, GAAP (USD)	$-1.12	$-1.62	$-2.94	$-2.01	—	—	—	—
Free Cash Flow per Share (USD)	$-1.11	$-1.28	$-1.49	$-1.78	—	—	—	—
Book Value per Share (USD)	$-1.48	$-2.05	$-1.80	$0.99	—	—	—	—
Tangible Book Value per Share (USD)	$-1.48	$-2.05	$-1.80	$0.99	—	—	—	—
Basic Weighted Avg Shares (shares)	127.07M	97.16M	81.71M	78.15M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Working Capital (USD)	$236.17M	$226.92M	$268.62M	$353.04M	—	—	—	—
Total Equity (USD)	$-185.83M	$-202.64M	$-148.25M	$79.45M	—	—	—	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Sales/Revenue/Turnover (USD)	$81.36M	$70.84M	$69.56M	$209.91M	—	—	—	—
Depreciation Expense (USD)	$705.00K	$1.33M	$1.19M	$1.06M	—	—	—	—
Net Income, GAAP (USD)	$-142.62M	$-157.85M	$-240.05M	$-157.13M	$-230.03M	$-246.29M	$-116.48M	$-123.10M
Operating Cash Flow (USD)	$-141.17M	$-123.83M	$-118.69M	$-138.31M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 17 quarters

ADC Therapeutics SA

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ADCT with peers